Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2020 ( 28 )

2019 ( 340 )

2018 ( 333 )

2017 ( 344 )

Custom range...

Search Results: 1 - 10 of 200558 matches for " Glen N.;Weiss "
All listed articles are free for downloading (OA Articles)
Page 1 /200558
Display every page Item
Pediatric lymphomas in Brazil
Gualco, Gabriela;Klumb, Claudete E.;Barber, Glen N.;Weiss, Lawrence M.;Bacchi, Carlos E.;
Clinics , 2010, DOI: 10.1590/S1807-59322010001200008
Abstract: objective: this study provides the clinical pathological characteristics of 1301 cases of pediatric/adolescent lymphomas in patients from different geographic regions of brazil. methods: a retrospective analyses of diagnosed pediatric lymphoma cases in a 10-year period was performed. we believe that it represents the largest series of pediatric lymphomas presented from brazil. results: non-hodgkin lymphomas represented 68% of the cases, including those of precursor (36%) and mature (64%) cell origin. mature cell lymphomas comprised 81% of the b-cell phenotype and 19% of the t-cell phenotype. hodgkin lymphomas represented 32% of all cases, including 87% of the classical type and 13% of nodular lymphocyte predominant type. the geographic distribution showed 38.4% of the cases in the southeast region, 28.7% in the northeast, 16.1% in the south, 8.8% in the north, and 8% in the central-west region. the distribution by age groups was 15-18 years old, 33%; 11-14 years old, 26%; 6-10 years old, 24%; and 6 years old or younger, 17%. among mature b-cell lymphomas, most of the cases were burkitt lymphomas (65%), followed by diffuse large b-cell lymphomas (24%). in the mature t-cell group, anaplastic large cell lymphoma, alk-positive was the most prevalent (57%), followed by peripheral t-cell lymphoma, then not otherwise specified (25%). in the group of classic hodgkin lymphomas, the main histological subtype was nodular sclerosis (76%). nodular lymphocyte predominance occurred more frequently than in other series. conclusion: some of the results found in this study may reflect the heterogeneous socioeconomical status and environmental factors of the brazilian population in different regions.
Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion
Glen J. Weiss,Agnes K. Liman,Jeffrey Allen,Philip Y. Cheung,Rajesh N. Kukunoor
Case Reports in Medicine , 2013, DOI: 10.1155/2013/874836
Abstract: We describe three confirmed cases of squamous cell carcinoma (SCC) of the lung with metastasis to the gastrointestinal (GI) tract, with two having epidermal growth factor receptor (EGFR) exon 19 deletions in all available specimens. One of these patients received EGFR tyrosine kinase directed therapy for a brief period with some symptom relief. Consideration of EGFR exon 19 mutation testing in SCC of the lung, particularly for those with GI tract metastasis, may identify this potentially drug-targetable entity. 1. Introduction Squamous cell carcinoma (SCC) of the lung metastasizing to the GI tract is an uncommon occurrence [1–4]. Epidermal growth factor receptor (EGFR) mutations have been identified in approximately 9% of metastatic SCC of the lung in one series [5]. We report on three patients with metastatic SCC of the lung metastasizing to the gastrointestinal (GI) tract, two of whom had tumor with a confirmed EGFR exon 19 deletion. 2. Case Presentations Case 1. A 39-year-old never-smoker man presented with cough, headaches, night sweats, 7-pound weight loss, and constipation for several weeks and was found to have multifocal metastases involving the lung, brain, and colon. A diagnostic colonoscopy was performed, and pathology confirmed metastatic SCC. Additional samples from the lung obtained by bronchoscopy demonstrated SCC consistent with a primary nonsmall cell lung cancer (NSCLC). He then underwent craniotomy and resection for a solitary cerebellar metastasis with pathology consistent with metastatic SCC of the lung. Subsequently, he was treated with cisplatin and gemcitabine, followed by vinorelbine and docetaxel for up to 3 cycles before developing extracranial disease progression. Tissues from the lung, brain, and colon underwent independent expert pathology review and confirmed metastatic SCC of the lung. Because of his never-smoker status, the brain metastasis sample was sent for EGFR mutation testing (exons 18–21) and found to have an EGFR exon 19 deletion. The patient was started on erlotinib and had a transient clinical response with resolution of night sweats and 4-pound weight gain. Three months later, progression by radiographic evidence of bone metastases was observed, and he passed away three weeks later. No postprogression sample was available for analysis. Case 2. A 79-year-old man with a 20-pack-year smoking history who was diagnosed with a 6.2?cm stage IIA T2bN0M0 SCC lung cancer underwent surgical resection. He also had a remote history of transitional cell carcinoma of the bladder. Adjuvant chemotherapy was not offered. Nearly
Molecular characterization of interdigitating dendritic cell sarcoma
Glen J. Weiss,Arlet Alarcon,Maqbool Halepota,Robert J. Penny
Rare Tumors , 2010, DOI: 10.4081/rt.2010.e50
Abstract: Interdigitating dendritic cell sarcoma is an extremely rare cancer that lacks a standard treatment approach. We report on a patient who was surgically resected and remains disease-free. The tumor was assessed for druggable targets using immunohistochemical staining to identify potential agents that could be used in the event of disease recurrence.
Basal cell adenocarcinoma of the supraglottic larynx: treatment of recurrent disease with tamoxifen
Christopher H. Bailey,Patrick J. Donovan,Glen J. Weiss
Rare Tumors , 2011, DOI: 10.4081/rt.2011.e55
Abstract: At the age of 83, a woman presented with an extremely rare cancer, basal cell adenocarcinoma (BCAC) of the supraglottic larynx. Pathology revealed a stage IVA tumor, pathological stage T4N0M0. She was treated with surgery and did not receive any adjuvant chemotherapy or radiation therapy. At the age of 93, during a routine examination, the patient was found to have palpable adenopathy and underwent a fine needle aspiration in June 2010. Pathology revealed similar histologic characteristics of her 2001 BCAC diagnosis, and further IHC stains revealed positive estrogen receptor staining.
Resolution of Cullen’s sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302
Glen J. Weiss,Karen Lewandowski,Jon Oneall,Stew Kroll
Dermatology Reports , 2011, DOI: 10.4081/dr.2011.e56
Abstract: Cullen’s sign, ecchymosis of the subcutaneous periumbilical tissue often described in association with non-malignant conditions such as ruptured ectopic pregnancy or acute pancreatitis, has been reported in malignancies involving the abdomen. In melanoma, hematoma-like metastasis has been observed and can resolve with an effective therapy. We observed resolution of Cullen’s sign (probably hematoma-like metastasis) in a patient with metastatic melanoma. The patient was participating in a phase I clinical trial and treated with TH-302, a hypoxia-activated prodrug. After 2 months on study, complete resolution of Cullen’s sign resolved in concert with extracranial response in lung, liver, and lymph node metastases. Based on the dramatic extracranial response to this investigational agent, additional patients with metastatic melanoma without evidence of brain metastasis were treated on study with TH-302.
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
Glen J. Weiss,Raoul Tibes,Lisa Blaydorn,Gayle Jameson
Dermatology Reports , 2011, DOI: 10.4081/dr.2011.e55
Abstract: Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for blood, mammary, and neural development. We report on our experience of treating two patients with advanced BCC participating. These two patients have had no new BCCs develop for at least 2.25 years. Both patients have been receiving ongoing daily treatment with vismodegib for greater than 2.75 years without experiencing any significant side effects. After prolonged continuous daily dosing with a SMO antagonist, we have not observed a significant alteration in hematologic parameters or physical abnormalities of the pectoral regions of two patients with advanced BCC.
Novel MicroRNA Candidates and miRNA-mRNA Pairs in Embryonic Stem (ES) Cells
Peili Gu, Jeffrey G. Reid, Xiaolian Gao, Chad A. Shaw, Chad Creighton, Peter L. Tran, Xiaochuan Zhou, Rafal B. Drabek, David L. Steffen, David M. Hoang, Michelle K. Weiss, Arash O. Naghavi, Jad El-daye, Mahjabeen F. Khan, Glen B. Legge, David A. Wheeler, Richard A. Gibbs, Jonathan N. Miller, Austin J. Cooney, Preethi H. Gunaratne
PLOS ONE , 2008, DOI: 10.1371/journal.pone.0002548
Abstract: Background MicroRNAs (miRNAs: a class of short non-coding RNAs) are emerging as important agents of post transcriptional gene regulation and integral components of gene networks. MiRNAs have been strongly linked to stem cells, which have a remarkable dual role in development. They can either continuously replenish themselves (self-renewal), or differentiate into cells that execute a limited number of specific actions (pluripotence). Methodology/Principal Findings In order to identify novel miRNAs from narrow windows of development we carried out an in silico search for micro-conserved elements (MCE) in adult tissue progenitor transcript sequences. A plethora of previously unknown miRNA candidates were revealed including 545 small RNAs that are enriched in embryonic stem (ES) cells over adult cells. Approximately 20% of these novel candidates are down-regulated in ES (Dicer?/?) ES cells that are impaired in miRNA maturation. The ES-enriched miRNA candidates exhibit distinct and opposite expression trends from mmu-mirs (an abundant class in adult tissues) during retinoic acid (RA)-induced ES cell differentiation. Significant perturbation of trends is found in both miRNAs and novel candidates in ES (GCNF?/?) cells, which display loss of repression of pluripotence genes upon differentiation. Conclusion/Significance Combining expression profile information with miRNA target prediction, we identified miRNA-mRNA pairs that correlate with ES cell pluripotence and differentiation. Perturbation of these pairs in the ES (GCNF?/?) mutant suggests a role for miRNAs in the core regulatory networks underlying ES cell self-renewal, pluripotence and differentiation.
Paired Tumor and Normal Whole Genome Sequencing of Metastatic Olfactory Neuroblastoma
Glen J. Weiss, Winnie S. Liang, Tyler Izatt, Shilpi Arora, Irene Cherni, Robert N. Raju, Galen Hostetter, Ahmet Kurdoglu, Alexis Christoforides, Shripad Sinari, Angela S. Baker, Raghu Metpally, Waibhav D. Tembe, Lori Phillips, Daniel D. Von Hoff, David W. Craig, John D. Carpten
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0037029
Abstract: Background Olfactory neuroblastoma (ONB) is a rare cancer of the sinonasal tract with little molecular characterization. We performed whole genome sequencing (WGS) on paired normal and tumor DNA from a patient with metastatic-ONB to identify the somatic alterations that might be drivers of tumorigenesis and/or metastatic progression. Methodology/Principal Findings Genomic DNA was isolated from fresh frozen tissue from a metastatic lesion and whole blood, followed by WGS at >30X depth, alignment and mapping, and mutation analyses. Sanger sequencing was used to confirm selected mutations. Sixty-two somatic short nucleotide variants (SNVs) and five deletions were identified inside coding regions, each causing a non-synonymous DNA sequence change. We selected seven SNVs and validated them by Sanger sequencing. In the metastatic ONB samples collected several months prior to WGS, all seven mutations were present. However, in the original surgical resection specimen (prior to evidence of metastatic disease), mutations in KDR, MYC, SIN3B, and NLRC4 genes were not present, suggesting that these were acquired with disease progression and/or as a result of post-treatment effects. Conclusions/Significance This work provides insight into the evolution of ONB cancer cells and provides a window into the more complex factors, including tumor clonality and multiple driver mutations.
Low-mass stars: Open problems all along their evolution
Weiss A.,Heners N.
EPJ Web of Conferences , 2013, DOI: 10.1051/epjconf/20134301002
Abstract: Although low-mass stars have a comparatively simple structure, current stellar models are far from reproducing them accurately. In light of the observational progress, in particular of asteroseismology, the deficits of the theory of stellar structure and evolution become increasingly evident, and can no longer be hidden under the carpet of observational errors. In my brief review I will discuss a number of obvious problems of the models, which are mainly – and not surprisingly so – connected with convective and other mixing processes. They begin already on the pre-main sequence and continue throughout the complete evolution. In addition to the deficits in the treatment of physical processes I will also address our difficulties in obtaining completely satisfying agreement between different numerical codes. It will be shown that this concerns already the main sequence evolution of low-mass stars without a convective core. Keeping this in mind, it is no surprise that models for stars on the Asymptotic Giant Branch differ widely.
Fallbericht: Hyponatri mie und Erregungszustand nach Verabreichung von Sertralin
Jelovac N,Weiss H
Journal für Neurologie, Neurochirurgie und Psychiatrie , 2006,
Page 1 /200558
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.